Published in Vaccine Weekly, January 26th, 2000
"DCs initiate primary and stimulate secondary T-cell responses," wrote J. E. Janik and colleagues from the U.S. National Cancer Institute, Maryland. "We conducted a phase I trial of tumor necrosis factor (TNF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with cancer to increase DCs in peripheral blood or skin."
According to the researchers, their idea was based on in vitro data that showed that CD34+ hematopoietic precursors require these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly